214 related articles for article (PubMed ID: 33996267)
1. Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa.
Ozawa Y; Hicks KC; Minnar CM; Knudson KM; Schlom J; Gameiro SR
Oncoimmunology; 2021 May; 10(1):1915561. PubMed ID: 33996267
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.
Gameiro SR; Strauss J; Gulley JL; Schlom J
Exp Biol Med (Maywood); 2022 Jul; 247(13):1124-1134. PubMed ID: 35473390
[TBL] [Abstract][Full Text] [Related]
3. Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
Gatti-Mays ME; Gameiro SR; Ozawa Y; Knudson KM; Hicks KC; Palena C; Cordes LM; Steinberg SM; Francis D; Karzai F; Lipkowitz S; Donahue RN; Jochems C; Schlom J; Gulley JL
Front Oncol; 2020; 10():581801. PubMed ID: 33747894
[TBL] [Abstract][Full Text] [Related]
4. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
Barlesi F; Isambert N; Felip E; Cho BC; Lee DH; Peguero J; Jerusalem G; Penel N; Saada-Bouzid E; Garrido P; Helwig C; Locke G; Ojalvo LS; Gulley JL
Oncologist; 2023 Mar; 28(3):258-267. PubMed ID: 36571770
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
[TBL] [Abstract][Full Text] [Related]
6. The Use of a Humanized NSG-β2m
Morillon YMI; Smalley Rumfield C; Pellom ST; Sabzevari A; Roller NT; Horn LA; Jochems C; Palena C; Greiner JW; Schlom J
Front Oncol; 2020; 10():549. PubMed ID: 32373533
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
Doi T; Fujiwara Y; Koyama T; Ikeda M; Helwig C; Watanabe M; Vugmeyster Y; Kudo M
Oncologist; 2020 Sep; 25(9):e1292-e1302. PubMed ID: 32324927
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461347
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types.
Wilkins JJ; Vugmeyster Y; Dussault I; Girard P; Khandelwal A
Adv Ther; 2019 Sep; 36(9):2414-2433. PubMed ID: 31278692
[TBL] [Abstract][Full Text] [Related]
10. Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa.
Tsai YT; Strauss J; Toney NJ; Jochems C; Venzon DJ; Gulley JL; Schlom J; Donahue RN
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35418484
[TBL] [Abstract][Full Text] [Related]
11. Radiolabelling and preclinical characterization of
Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805
[TBL] [Abstract][Full Text] [Related]
12. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
[TBL] [Abstract][Full Text] [Related]
13. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
Strauss J; Gatti-Mays ME; Cho BC; Hill A; Salas S; McClay E; Redman JM; Sater HA; Donahue RN; Jochems C; Lamping E; Burmeister A; Marté JL; Cordes LM; Bilusic M; Karzai F; Ojalvo LS; Jehl G; Rolfe PA; Hinrichs CS; Madan RA; Schlom J; Gulley JL
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323462
[TBL] [Abstract][Full Text] [Related]
14. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
Spira A; Wertheim MS; Kim EJ; Tan B; Lenz HJ; Nikolinakos P; Rich PL; Jehl G; Machl A; Ito R; Gulley JL; Kopetz S
Oncologist; 2023 Feb; 28(2):e124-e127. PubMed ID: 36576431
[TBL] [Abstract][Full Text] [Related]
15. Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy.
Tschernia NP; Gulley JL
BioDrugs; 2022 Mar; 36(2):153-180. PubMed ID: 35353346
[TBL] [Abstract][Full Text] [Related]
16. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Cho BC; Daste A; Ravaud A; Salas S; Isambert N; McClay E; Awada A; Borel C; Ojalvo LS; Helwig C; Rolfe PA; Gulley JL; Penel N
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641320
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
[TBL] [Abstract][Full Text] [Related]
18. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
Paz-Ares L; Kim TM; Vicente D; Felip E; Lee DH; Lee KH; Lin CC; Flor MJ; Di Nicola M; Alvarez RM; Dussault I; Helwig C; Ojalvo LS; Gulley JL; Cho BC
J Thorac Oncol; 2020 Jul; 15(7):1210-1222. PubMed ID: 32173464
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
20. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
Tan B; Khattak A; Felip E; Kelly K; Rich P; Wang D; Helwig C; Dussault I; Ojalvo LS; Isambert N
Target Oncol; 2021 Jul; 16(4):435-446. PubMed ID: 34009501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
